Cwm LLC Sells 1,590 Shares of Royalty Pharma plc (NASDAQ:RPRX)

Cwm LLC cut its holdings in Royalty Pharma plc (NASDAQ:RPRX) by 22.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,473 shares of the biopharmaceutical company’s stock after selling 1,590 shares during the quarter. Cwm LLC’s holdings in Royalty Pharma were worth $155,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of RPRX. Versant Capital Management Inc increased its position in shares of Royalty Pharma by 5,215.0% during the second quarter. Versant Capital Management Inc now owns 1,063 shares of the biopharmaceutical company’s stock valued at $28,000 after buying an additional 1,043 shares during the period. Gladius Capital Management LP bought a new stake in Royalty Pharma during the 2nd quarter valued at approximately $32,000. Fidelis Capital Partners LLC purchased a new position in shares of Royalty Pharma during the 1st quarter worth approximately $46,000. EverSource Wealth Advisors LLC raised its position in shares of Royalty Pharma by 32.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,698 shares of the biopharmaceutical company’s stock worth $76,000 after acquiring an additional 655 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Royalty Pharma by 4,335.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 2,750 shares of the biopharmaceutical company’s stock valued at $84,000 after purchasing an additional 2,688 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the stock. Morgan Stanley lifted their target price on shares of Royalty Pharma from $48.00 to $51.00 and gave the company an “overweight” rating in a report on Thursday, July 11th. StockNews.com raised Royalty Pharma from a “hold” rating to a “buy” rating in a research report on Tuesday, September 17th. Finally, The Goldman Sachs Group boosted their target price on Royalty Pharma from $50.00 to $51.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Royalty Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $42.00.

Royalty Pharma Trading Down 0.0 %

NASDAQ:RPRX opened at $27.36 on Thursday. The firm has a 50-day simple moving average of $28.02 and a 200-day simple moving average of $27.65. Royalty Pharma plc has a one year low of $25.20 and a one year high of $31.66. The firm has a market cap of $16.24 billion, a P/E ratio of 24.21, a P/E/G ratio of 4.12 and a beta of 0.46. The company has a debt-to-equity ratio of 0.78, a quick ratio of 9.35 and a current ratio of 9.35.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.95 by $0.01. The company had revenue of $537.00 million during the quarter, compared to analysts’ expectations of $600.83 million. Royalty Pharma had a net margin of 30.08% and a return on equity of 23.61%. During the same quarter in the prior year, the company posted $0.85 earnings per share. Equities analysts anticipate that Royalty Pharma plc will post 4.05 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $0.21 per share. The ex-dividend date of this dividend is Friday, November 15th. This represents a $0.84 dividend on an annualized basis and a yield of 3.07%. Royalty Pharma’s dividend payout ratio is presently 74.34%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.